Contract development and manufacturing organizations (CDMOs) are grappling with persistent capacity constraints as demand for biopharmaceutical manufacturing surges. A recent survey by BioPlan Associates reveals that nearly half of biopharma companies report significant challenges in securing CDMO capacity, particularly for mammalian production, where 49% of respondents indicated difficulties. This is an increase from previous years, reflecting an ongoing trend of escalating demand amidst limited supply.
The implications of these constraints are profound, particularly for advanced therapies such as gene and cell therapies, which are heavily reliant on specialized CDMO capabilities. With 55.9% of companies struggling to find capacity in gene therapy and 55.6% in cell therapy, the bottleneck is not merely a matter of available space but also the specialized expertise required for these complex processes. As the industry evolves, the gap between demand and capacity may hinder the timely development of innovative therapies, necessitating strategic investments and operational flexibility from CDMOs to meet the diverse needs of biopharma sponsors.
Open the full market picture for your next decision →
